Which of the following is approved for the treatment of cystic fibrosis with G551D mutation?: (A) Biostrophin, (B) Peginesatide, (C) Lumacaftor, (D) Ivacaftor
Answer is D. Biostrophin is a vehicle for gene therapy in Duchenne and Becker's muscular dystrophyPeginesatide is an erythropoietin analog for anemia of chronic kidney diseaseLumacaftor is a CFTR potentiator for cystic fibrosis with F508 mutationIvacaftor is a CFTR potentiator for cystic fibrosis with G551D mutation